Clinical trial NCT02650544 - References

Depression — Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression

Citation(s)

•   Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M
  Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther. 2005 Apr;30(2):133-8.
•   Andersen BL, Rowland JH, Somerfield MR
  Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an american society of clinical oncology guideline adaptation. J Oncol Pract. 2015 Mar;11(2):133-4. doi: 10.1200/JOP.2014.002311. Epub 2014 Dec 16.
•   Anttila SA, Leinonen EV
  A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. Review.
•   Arrieta O, Angulo LP, Núñez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martínez-López D, Alvarado S, Corona-Cruz JF, Oñate-Ocaña LF
  Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. 2013 Jun;20(6):1941-8. doi: 10.1245/s10434-012-2793-5. Epub 2012 Dec 22.
•   Badr H, Shen MJ
  Pain catastrophizing, pain intensity, and dyadic adjustment influence patient and partner depression in metastatic breast cancer. Clin J Pain. 2014 Nov;30(11):923-33. doi: 10.1097/AJP.0000000000000058.
•   Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O
  miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science. 2010 Sep 17;329(5998):1537-41. doi: 10.1126/science.1193692.
•   Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D, Corrada D, Milanesi L, Gennarelli M
  Blood microRNA changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol. 2013 Jul;23(7):602-11. doi: 10.1016/j.euroneuro.2012.06.013. Epub 2012 Aug 25.
•   Burrows GD, Kremer CM
  Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. Review.
•   de Souza BF, de Moraes JA, Inocenti A, dos Santos MA, Silva AE, Miasso AI
  Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence. Rev Lat Am Enfermagem. 2014 Oct;22(5):866-73. English, Portuguese, Spanish.
•   HAMILTON M
  A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.
•   Hopwood P, Stephens RJ
  Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000 Feb;18(4):893-903.
•   Huntzinger E, Izaurralde E
  Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011 Feb;12(2):99-110. doi: 10.1038/nrg2936. Review.
•   Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R, Gil S, Mayberg HS, Dunlop BW, Menke A, Awatramani R, Binder EB, Deneris ES, Lowry CA, Chen A
  MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron. 2014 Jul 16;83(2):344-60. doi: 10.1016/j.neuron.2014.05.042. Epub 2014 Jun 19.
•   Ito T, Okubo Y, Roth A
  [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center]. Gan To Kagaku Ryoho. 2009 Apr;36(4):623-6. Japanese. Retraction in: Ito T, Sato H. Gan To Kagaku Ryoho. 2009 Oct;36(10):1779.
•   Karakas SA, Okanli A
  The relationship between meaning of illness, anxiety depression, and quality of life for cancer patients. Coll Antropol. 2014 Sep;38(3):939-44.
•   Lee Y, Lin PY, Chien CY, Fang FM
  Prevalence and risk factors of depressive disorder in caregivers of patients with head and neck cancer. Psychooncology. 2015 Feb;24(2):155-61. doi: 10.1002/pon.3619. Epub 2014 Jul 10.
•   Lotrich FE
  Inflammatory cytokine-associated depression. Brain Res. 2015 Aug 18;1617:113-25. doi: 10.1016/j.brainres.2014.06.032. Epub 2014 Jul 5. Review.
•   Massie MJ
  Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;(32):57-71. Review.
•   Popoli M, Yan Z, McEwen BS, Sanacora G
  The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011 Nov 30;13(1):22-37. doi: 10.1038/nrn3138. Review.
•   Puzantian T
  Mirtazapine, an antidepressant. Am J Health Syst Pharm. 1998 Jan 1;55(1):44-9. Review.
•   Reddy MS
  Depression: the disorder and the burden. Indian J Psychol Med. 2010 Jan;32(1):1-2. doi: 10.4103/0253-7176.70510.
•   Rodin G
  Effective treatment for depression in patients with cancer. Lancet. 2014 Sep 20;384(9948):1076-8. doi: 10.1016/S0140-6736(14)61342-8. Epub 2014 Aug 28.
•   Sanacora G, Treccani G, Popoli M
  Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012 Jan;62(1):63-77. doi: 10.1016/j.neuropharm.2011.07.036. Epub 2011 Aug 3. Review.
•   Sharpe M, Walker J, Holm Hansen C, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G; SMaRT (Symptom Management Research Trials) Oncology-2 Team
  Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet. 2014 Sep 20;384(9948):1099-108. doi: 10.1016/S0140-6736(14)61231-9. Epub 2014 Aug 27.
•   Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y
  MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One. 2012;7(3):e33201. doi: 10.1371/journal.pone.0033201. Epub 2012 Mar 9.
•   Spiegel D
  Minding the body: psychotherapy and cancer survival. Br J Health Psychol. 2014 Sep;19(3):465-85. doi: 10.1111/bjhp.12061. Epub 2013 Aug 26. Review.
•   Stafford L, Judd F, Gibson P, Komiti A, Mann GB, Quinn M
  Anxiety and depression symptoms in the 2 years following diagnosis of breast or gynaecologic cancer: prevalence, course and determinants of outcome. Support Care Cancer. 2015 Aug;23(8):2215-24. doi: 10.1007/s00520-014-2571-y. Epub 2015 Jan 6.
•   Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ
  Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.
•   Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD
  An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002 May;23(5):442-7.
•   Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G, Sharpe M; SMaRT (Symptom Management Research Trials) Oncology-3 Team
  Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol. 2014 Sep;15(10):1168-76. doi: 10.1016/S1470-2045(14)70343-2. Epub 2014 Aug 27.
•   Zeng LH, Rensing NR, Wong M
  Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway. Mol Cell Pharmacol. 2009 Jan 1;1(3):124-129.

Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients

Details for clinical trial NCT02650544